Prevalence of Prolonged QTC Interval in Patients Taking Psychopharmacs

1. Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig. 2015; 12(2):242-8.10.4306/pi.2015.12.2.242439059625866526Search in Google Scholar

2. Rouillon F, Van Ganse E, Vekhoff P, Arnaud R, Depret-Bixio L, Dillenschneider A. Vigilance level for cardiovascular risk factors in schizophrenic patients. Encephale. 2015;41(1):70-7.10.1016/j.encep.2014.12.00325637197Search in Google Scholar

3. Cradock-O’Leary J, Young AS, Yano EM, Wang M, Lee ML. Use of general medical services by VA patients with psychiatric disorders. Psychiatr Serv. 2002;53(7):874-8.10.1176/appi.ps.53.7.87412096172Open DOISearch in Google Scholar

4. Jones ME, Campbell G, Patel D, Brunner E, Shatapathy CC, Murray-Thomas T, van Staa TP, Motsko S. Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics: A Study with the General Practice Research Database. Cardiovasc Psychiatry Neurol. 2013;2013:647476.10.1155/2013/647476387659224416588Search in Google Scholar

5. Tolliver BK, Anton RF. Assessment and treatment of mood disorders in the context of substance abuse. Dialogues Clin Neurosci. 2015;17(2):181-90.10.31887/DCNS.2015.17.2/btolliverSearch in Google Scholar

6. Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M.2013 Annual Report of the American Association of Poison Control Centers’ National Poison Data System: 31th Annual Report. Clin Toxicol. 2014;52:1032–283.10.3109/15563650.2014.987397478268425559822Search in Google Scholar

7. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Fosbøl EL, Wissenberg M, Lippert FK, Christensen EF, Nielsen SL, Holm E, Kanters JK, Poulsen HE, Køber L, Torp-Pedersen C. Antipsychotics and associated risk of out-of-hospital cardiac arrest. Clin Pharmacol Ther. 2014;96(4):490-7.10.1038/clpt.2014.13924960522Open DOISearch in Google Scholar

8. Nezafati MH, Vojdanparast M, Nezafati P. Antidepressants and cardiovascular adverse events: A narrative review. ARYA Atheroscler. 2015;11(5):295-304.Search in Google Scholar

9. Zemrak WR, George A. Kenna GA. Association of Antipsychotic and Antidepressant Drugs With Q-T interval Prolongation. Am J Health Syst Pharm. 2008;65(11):1029-1038.10.2146/ajhp07027918499875Open DOISearch in Google Scholar

10. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920.10.1007/s40263-014-0196-925168784Search in Google Scholar

11. Postema PG, Wilde AA. The Measurement of the QT Interval. Current Cardiology Reviews. 2014;10(3):287-294.10.2174/1573403X10666140514103612Open DOISearch in Google Scholar

12. Committee for Proprietary Medicinal Products. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, Committee for Proprietary Medicinal Products, London (1997).Search in Google Scholar

13. De Bruin ML, Langendijk PN, Koopmans RP, Wilde AA, Leufkens HG, Hoes AW. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2007;63:216–223.10.1111/j.1365-2125.2006.02722.x200057816869820Open DOISearch in Google Scholar

14. Huffman JC, Stern TA. QTc Prolongation and the Use of Antipsychotics: A Case Discussion. Prim Care Companion J Clin Psychiatry. 2003;5(6):278-281.10.4088/PCC.v05n0605Search in Google Scholar

15. Vieweg WV. New Generation Antipsychotic Drugs and QTc Interval Prolongation.Prim Care Companion J Clin Psychiatry. 2003;5(5):205-215.10.4088/PCC.v05n050441929915213787Search in Google Scholar

16. Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. Am J Psychiatry. 2013;170(12):1468-76.10.1176/appi.ajp.2013.1206086024306340Search in Google Scholar

17. Wenzel-Seifert K, Wittmann M, Haen E. QTc Prolongation by Psychotropic Drugs and the Risk of Torsade de Pointes. Dtsch Arztebl Int. 2011; 108(41): 687–693.10.3238/arztebl.2011.0687322142722114630Search in Google Scholar

18. Alinejad S, Kazemi T, Zamani N, Hoffman RS, Mehrpour O. A systematic review of the cardiotoxicity of methadone. EXCLI J. 2015;14:577-600.Search in Google Scholar

19. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol. 2016;81(4):773-83.10.1111/bcp.12829479992926574175Open DOISearch in Google Scholar

20. Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology FoundationEndorsed by the American Association of Critical-Care Nurses and the International Society for Computerized Electrocardiology. Circulation. 2010;121(8):1047-1060.10.1161/CIRCULATIONAHA.109.192704305612320142454Search in Google Scholar

21. Anonymous (2005b). International Conference on Harmonisation; guidance on S7b Nonclinical evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals; availability. Notice. Fed Regist 70:61133–61134.Search in Google Scholar

22. Anonymous (2005a). International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Fed Regist 70: 61134–61135.Search in Google Scholar

23. CredibleMeds® QTDrugs Lists [cited 05 August 2014]. Available: https://www.crediblemeds.org. Accessed 5 June 2016.Search in Google Scholar

24. Schächtele S, Tümena T, Gaßmann KG, Fromm MF, Maas R. Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients. PLoS One. 2016;11(5):e0155649.10.1371/journal.pone.0155649487141327192430Search in Google Scholar

25. Vicente J, Johannesen L, Galeotti L, Strauss DG. Mechanisms of sex and age differences in ventricular repolarization in humans. Am Heart J. 2014;168(5):749-56).10.1016/j.ahj.2014.07.01025440804Search in Google Scholar

26. Sumić JČ, Barić V, Bilić P, Herceg M, Sisek-Šprem M, Jukić V. QTc and psychopharmacs: are there any differences between monotherapy and polytherapy. Annals of General Psychiatry. 2007;6:13.10.1186/1744-859X-6-13187159017477877Search in Google Scholar

27. Sala M, Vicentini A, Brambilla P et al. QT interval prolongation related to psycho-active drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005; 4:1.10.1186/1744-859X-4-1Search in Google Scholar

28. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand. 2003;107(2):85-95.10.1034/j.1600-0447.2003.02078.xSearch in Google Scholar

29. Harrigan EP, Miceli JJ, Anziano R et al. A randomized evaluation of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004; 24:62-9.10.1097/01.jcp.0000104913.75206.62Search in Google Scholar

30. Curto M, Girardi N, Lionetto L, Ciavarella GM, Ferracuti S, Baldessarini RJ. Systematic Review of Clozapine Cardiotoxicity. Curr Psychiatry Rep. 2016;18(7):68.10.1007/s11920-016-0704-3Search in Google Scholar

31. Lam RW. Psychopharmacology for the Clinician. J Psychiatry Neurosci. 2013; 38(2): E5–E6.10.1503/jpn.120256Search in Google Scholar

32. Stringer J, Welsh Ch, Tommasello A. Methadone-associated Q-T Interval Prolongation and Torsades de Pointes. Am J Health Syst Pharm. 2009;66(9):825-833.10.2146/ajhp070392Open DOISearch in Google Scholar

33. Viskin S, Rosovski U, Sands AJ, Chen E, Kistler PM, Kalman JM, Rodriguez Chavez L, Iturralde Torres P, Cruz FFE, Centurion OA, Fujiki A, Maury P, Chen X, Krahn AD, Roithinger F, Zhang L, Vincent GM, Zeltser D: Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one. Heart Rhythm 2005;2: 569-574.10.1016/j.hrthm.2005.02.011Open DOISearch in Google Scholar

34. M.Vega, C. Riaza, A. Chinchilla, I. Gobernado. HYPOKALEMIA, PSYCHOMOTOR AGITATION AND PROLONGING THE QTC. European Psychiatry 2011.10.1016/S0924-9338(11)72457-9Search in Google Scholar

35. Molnar J, Zhang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol. 1996;27(1):76–83.10.1016/0735-1097(95)00426-2Open DOISearch in Google Scholar

36. Zitron E, Scholz E, Owen RW, Lück S, Kiesecker C, Thomas D, et al. QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids. Circulation. 2005;111:835–838.10.1161/01.CIR.0000155617.54749.0915710766Search in Google Scholar

37. Goldenberg I, Moss AJ, Zareba W. QT Interval: How to Measure It and What Is “Normal”. J Cardiovasc Electrophysiol. 2006;17(3):333-6.10.1111/j.1540-8167.2006.00408.x16643414Search in Google Scholar

38. Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R, Johnson G, Piepho R, Vieweg V; Cardiac Safety in Schizophrenia Group. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Encephale. 2002; 28(6 Pt 1):552-62.Search in Google Scholar